The Potential of Cannabidiol for Acute Respiratory Distress Syndrome in COVID-19.

Saeid Azimi, Fatemeh Saghafi, Mohammad Hossein Mohammadi, Mohammad Hossein Moghimi, Seyed Ali Akhavan, Masoud Khataminia, Maria Shirvani, Seyed Mojtaba Sohrevardi, Tannaz Jamialahmadi, Adeleh Sahebnasagh, Amirhossein Sahebkar

Journal: Current pharmaceutical design 2023;29(29):2291-2296

PMID: 37818584

Full Text on Ingenta plc View on PubMed

Abstract

COVID-19 disease manifests itself in a wide range of signs and symptoms, beginning with mild symptoms, such as fever, cough, and dyspnea, progressing to acute respiratory distress syndrome (ARDS) and death in some cases. The cytokine storm, or an excess of cytokines released locally, is assumed to be the primary cause of ARDS and mortality in COVID-19 patients. To enhance the survival rate of COVID-19 patients, early management of the cytokine storm with immunomodulators is crucial. Although the effectiveness of some immunosuppressants, such as corticosteroids and tocilizumab, has been studied in clinical trials, the administration of these drugs should be exercised cautiously. Cannabidiol (CBD) is a non-psychotropic phytocannabinoid from Cannabis sativa extracts with anti-inflammatory properties. This review is intended to discuss the possible utility of CBD for the management of COVID-19 patients, particularly those with ARDS.

Address: Student Research Committee, Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.; Department of Clinical Pharmacy, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.; Shahid Sadoughi University of Medical Sciences, Yazd, Iran.; Student Research Committee, Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.; Student Research Committee, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.; Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.; Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.; Department of Internal Medicine, Clinical Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran.; Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.

DOI: 10.2174/0113816128275803230920094909

Link outs

Free resources

Medical:

https://medlineplus.gov/covid19coronavirusdisease2...

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, COVID-19, Cannabidiol, Cytokine Release Syndrome, Respiratory Distress Syndrome, Cytokines